Fennec Pharma Confirms Nasdaq Listing for Common Shares
Ticker: FENC · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, exchange-listing, corporate-governance
TL;DR
**Fennec Pharma just confirmed its common shares are still listed on Nasdaq, no delisting worries here.**
AI Summary
Fennec Pharmaceuticals Inc. filed an 8-K on February 1, 2024, to update its registration for common shares on the Nasdaq Capital Market. This filing confirms the company's continued compliance with exchange listing requirements, which is crucial for maintaining investor access and liquidity. For shareholders, this means the company's stock, FENC, remains readily tradable on a major exchange, reducing potential concerns about delisting and ensuring ongoing market visibility.
Why It Matters
This filing confirms Fennec Pharmaceuticals' continued listing on the Nasdaq Capital Market, which is vital for maintaining liquidity and investor confidence in its common shares (FENC).
Risk Assessment
Risk Level: low — This filing is a routine update confirming existing information and does not introduce new risks or significant changes to the company's operations or financial standing.
Analyst Insight
An investor should view this as a routine compliance filing, confirming the company's continued listing on a major exchange. It doesn't provide new information to warrant immediate action but reinforces the stability of the stock's trading venue.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where Fennec's common shares are registered
- FENC (company) — the trading symbol for Fennec Pharmaceuticals' common shares
- February 1, 2024 (date) — the date of the earliest event reported in the 8-K
FAQ
What is the purpose of this 8-K filing by Fennec Pharmaceuticals Inc.?
The purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits,' specifically confirming the registration of its Common shares, no par value, on the Nasdaq Capital Market, as of the earliest event reported on February 1, 2024.
What is the trading symbol for Fennec Pharmaceuticals Inc. on the Nasdaq Capital Market?
The trading symbol for Fennec Pharmaceuticals Inc.'s common shares on the Nasdaq Capital Market is FENC, as stated in the 'Securities registered pursuant to Section 12 of the Act' section of the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 1, 2024, as indicated by 'Date of Report (Date of earliest event reported): February 1, 2024'.
What is Fennec Pharmaceuticals Inc.'s Commission File Number?
Fennec Pharmaceuticals Inc.'s Commission File Number is 001-32295, as specified in the filing.
Where is Fennec Pharmaceuticals Inc.'s principal executive office located?
Fennec Pharmaceuticals Inc.'s principal executive office is located at PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC 27709, according to the business address provided in the filing.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-02-01 18:42:56
Filing Documents
- tm244893d1_8k.htm (8-K) — 25KB
- tm244893d1_ex99-1.htm (EX-99.1) — 9KB
- tm244893d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-009551.txt ( ) — 211KB
- fencf-20240201.xsd (EX-101.SCH) — 3KB
- fencf-20240201_lab.xml (EX-101.LAB) — 33KB
- fencf-20240201_pre.xml (EX-101.PRE) — 22KB
- tm244893d1_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. On February 1, 2024, Fennec Pharmaceuticals Inc. issued a news release announcing the U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. PEDMARK is the first and only FDA approved therapy indicated to reduce the risk of ototoxicity (e.g., permanent hearing loss) associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated February 1, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date February 1, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer